N-<(2R)-2-(8-isobutyl-6-phenyl-1,2,4-triazolo<4,3-a>pyrazin-3-yl)-3-pyridin-3-ylpropanoyl>-ACHPA-Leu-m-(aminomethyl)benzylamide | 128972-41-8

• 分子结构分类: 有机化合物 - 脂质和类脂质分子
• 英文名称: N-<(2R)-2-(8-isobutyl-6-phenyl-1,2,4-triazolo<4,3-a>pyrazin-3-yl)-3-pyridin-3-ylpropanoyl>-ACHPA-Leu-m-(aminomethyl)benzylamide
• 英文别名: N-[(2R)-2-(8-isobutyl-6-phenyl-1,2,4-triazolo[4,3-a]pyrazin-3-yl)-3-pyridin-3-ylpropanoyl]-ACHPA-Leu-m-(aminomethyl)benzylamide
• CAS: 128972-41-8；129096-84-0
• 化学式: C₄₈H₆₃N₉O₄
• 分子量: 830.086
• InChiKey: IXDWTEYIKGOOJY-FHBNTUAESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.22
• 重原子数：
  61.0
• 可旋转键数：
  20.0
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.48
• 拓扑面积：
  189.52
• 氢给体数：
  5.0
• 氢受体数：
  10.0

反应信息

• 作为产物：
  描述：

  2-chloro-3-propyl-5-(pyridin-3-yl)pyrazine 在 palladium on activated charcoal sodium hydroxide 、 氢气 、 sodium hydride 、 1-羟基苯并三唑 、 对甲苯磺酸 、 一水合肼 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 作用下， 以 乙醇 、 二甲基亚砜 、 乙酸乙酯 、 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 28.5h， 生成 N-<(2R)-2-(8-isobutyl-6-phenyl-1,2,4-triazolo<4,3-a>pyrazin-3-yl)-3-pyridin-3-ylpropanoyl>-ACHPA-Leu-m-(aminomethyl)benzylamide
  参考文献：
  名称：

  1,2,4-Triazolo[4,3-a]pyrazine derivatives with human renin inhibitory activity. 1. Synthesis and biological properties of alkyl alcohol and statine derivatives

  摘要：

  A series of 1,2,4-triazolo[4,3-a]pyrazine derivatives with human renin inhibitory activity, which incorporate (1S,2S)-2-amino-1,3-dicyclohexyl-1-hydroxypropane, statine (Sta), and (3S,4S)-4-amino-5-cyclohexyl-3-hydroxy-pentanoic acid (ACHPA) transition-state mimetics, have been prepared. Structure-activity relationships for renin inhibitory activity in the series are consistent with the 2-[8-isobutyl-6-phenyl-1,2,4-triazolo[4,3-a]pyrazin-3-yl]-3-(3 pyridyl)propionic acid moiety 10b acting as a non-peptidic replacement for the P4-P2 (Pro-Phe-His) residues of the natural substrate angiotensinogen. Compounds 12m, 12o and 12q were potent inhibitors of partially purified human renin (IC50 values 1.7, 6.8, and 3.7 nM, respectively), and also effectively lowered blood pressure in anesthetized, sodium depleted marmosets following intravenous administration. On oral administration however, no blood pressure lowering activity could be detected, and absorption studies in bile duct cannulated rats indicate that this may be due primarily to poor oral absorption, rather than rapid biliary excretion. The reason for the observed poor oral activity is not clear, but it seems unlikely that poor aqueous solubility or metabolic instability to gut enzymes are rate-determining, and other factors such as high molecular weight may also be very important.

  DOI：

  10.1021/jm00171a005